Fisher, J E <br/><br/>
Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro.  [electronic resource] 

 -  Proceedings of the National Academy of Sciences of the United States of America  Jan 1999 
 - 133-8 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0027-8424 
<br/><br/><label>Standard No.: </label>10.1073/pnas.96.1.133  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Alendronate--pharmacology<br/>Animals<br/>Bone Resorption--metabolism<br/>Cell Differentiation--drug effects<br/>Cells, Cultured<br/>Cholesterol--biosynthesis<br/>Clodronic Acid--pharmacology<br/>Diterpenes--pharmacology<br/>Enzyme Activation--drug effects<br/>Farnesol--pharmacology<br/>Hydroxymethylglutaryl-CoA Reductase Inhibitors--pharmacology<br/>Lovastatin--pharmacology<br/>Mevalonic Acid--metabolism<br/>Mice<br/>Osteoclasts--cytology<br/>Protein Kinases--metabolism<br/>Rabbits<br/>Skull--metabolism<br/>Squalene--pharmacology